Stocks · News reference

Hemab Advances Bleeding Disorder Pipeline

Jul 13, 2026, 5:47 PMVandana Singh

Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARSep 24, 2026, 8:03 PMSEC EDGAR
8-K filing — Hemab Therapeutics Holdings, Inc. (COAG)
Filed: 2026-09-24 AccNo: 0001193125-26-401010 Size: 145 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
COAG
BenzingaSep 17, 2026, 12:04 PMBenzinga Newsdesk
Hemab Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Trial Of HMB-003 For Heavy Menstrual Bleeding; Says Results Expected No Later Than Mid-2027
COAG
BenzingaAug 31, 2026, 8:53 AMAvi Kapoor
Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in Aug. 2026,
AEHL CHAI COAG COOT ELMT
BenzingaAug 12, 2026, 4:06 PMBenzinga Newsdesk
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
COAG